Pfizer Stock: Bear vs. Bull
Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be alluring, investors need to understand the questions surrounding its future pace of growth if they're considering a purchase.
With that being said, here's a pair of perspectives on the stock, one from the bulls, and one from the bears. The one thing both arguments agree on is that the company's future won't look like its recent past.
The bull thesis for Pfizer rests on its ambitious strategic plan to grow its annual revenue to $84 billion by 2030 via a combination of launching new drugs and buying assets or making acquisitions. The company believes the products it expects to launch in the coming months could generate $20 billion in annual sales by the end of the decade. That's in addition to the $25 billion in additional revenue it expects to bring in via business development deals.
Source Fool.com
Pfizer Inc. Stock
With 31 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 58.61% for Pfizer Inc. compared to the current price of 25.85 €.
